Biogen Stock Price, News & Analysis (NASDAQ:BIIB)

22 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Biogen in the last year. There are currently 4 hold ratings and 18 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" BIIB shares.
View BIIB analyst ratings or view top-rated stocks.

22 analysts have issued 12-month target prices for Biogen's stock. Their BIIB share price targets range from $239.00 to $373.00. On average, they anticipate the company's share price to reach $323.00 in the next twelve months. This suggests a possible upside of 40.7% from the stock's current price.
View analysts price targets for BIIB or view top-rated stocks among Wall Street analysts.

Biogen's stock was trading at $276.92 at the beginning of the year. Since then, BIIB shares have decreased by 17.1% and is now trading at $229.57.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 21st 2024.
View our BIIB earnings forecast.

Biogen Inc. (NASDAQ:BIIB) posted its quarterly earnings results on Wednesday, November, 8th. The biotechnology company reported $4.36 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.99 by $0.37. The biotechnology company had revenue of $2.53 billion for the quarter, compared to analyst estimates of $2.40 billion. Biogen had a net margin of 14.63% and a trailing twelve-month return on equity of 16.40%. The company's revenue for the quarter was up .9% on a year-over-year basis. During the same period in the prior year, the business posted $4.77 EPS.
Read the conference call transcript.

ETFs with the largest weight of Biogen (NASDAQ:BIIB) stock in their portfolio include Horizon Kinetics Medical ETF (MEDX), VanEck Biotech ETF (BBH), Invesco Biotechnology & Genome ETF (PBE), Subversive Mental Health ETF (SANE), iShares Neuroscience and Healthcare ETF (IBRN), Invesco Nasdaq Biotechnology ETF (IBBQ), iShares Biotechnology ETF (IBB) and Goldman Sachs Future Health Care Equity ETF (GDOC).

Biogen updated its FY23 earnings guidance on Wednesday, November, 8th. The company provided earnings per share (EPS) guidance of $14.50-15.00 for the period, compared to the consensus earnings per share estimate of $15.29.

394 employees have rated Biogen Chief Executive Officer Michel Vounatsos on Glassdoor.com. Michel Vounatsos has an approval rating of 86% among the company's employees. 72.0% of employees surveyed would recommend working at Biogen to a friend.

Based on aggregate information from My MarketBeat watchlists, some companies that other Biogen investors own include NVIDIA (NVDA), Gilead Sciences (GILD), Netflix (NFLX), Tesla (TSLA), Alibaba Group (BABA), Amgen (AMGN), Walt Disney (DIS), Intel (INTC), Micron Technology (MU) and Boeing (BA).

Biogen's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Primecap Management Co. CA (11.05%), Wellington Management Group LLP (3.71%), Clearbridge Investments LLC (1.26%), Northern Trust Corp (1.13%), Morgan Stanley (1.03%) and Bank of New York Mellon Corp (0.99%). Insiders that own company stock include Alfred Sandrock, Brian S Posner, Ginger Gregory, Priya Singhal and Susan H Alexander.
View institutional ownership trends.

Shares of BIIB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.